Cancer vaccine composition comprising calcium lactate as active ingredient and use thereof

The cancer vaccine composition using calcium lactate and specific cytokines and antigens induces necroptosis and STING activation, effectively targeting cancer cells and enhancing immune response to prevent recurrence.

WO2024242545A1PCT designated stage expired Publication Date: 2024-11-28METIMEDI PHARMA CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/095840
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-09
Filing Date
2024-05-22
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current cancer treatments, including chemotherapy and traditional vaccines, face limitations in effectively targeting and eliminating cancer stem cells and metastatic sites, particularly brain metastases, with short-lived responses and eventual tumor recurrence, due to immune evasion mechanisms and inadequate immune activation.

Method used

A cancer vaccine composition containing calcium lactate as an active ingredient, combined with tumor-specific antigens, cytokines like IL-2, IL-7, IL-12, IL-15, IL-21, and GM-CSF, and monosodium phosphate, which induces necroptosis and activates STING to enhance immune response and anti-tumor immunity.

Benefits of technology

The composition induces apoptosis and necroptosis in cancer cells, promotes a sustained immune response, and reduces tumor burden by activating cytotoxic T-lymphocytes, providing a therapeutic preventive benefit against cancer recurrence with minimal toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024095840_28112024_PF_FP_ABST
    Figure KR2024095840_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition comprising, as active ingredients: a) calcium lactate; and b) at least one substance selected from the group consisting of a phosphate, stem cell, cytokine, cancer cell line, antigen derived from the cancer cell line, polynucleotide encoding the antigen, antigen gene construct in which the polynucleotide is operably linked to a promoter, and expression vector comprising the gene construct. The composition of the present invention has an anti-tumor immunological memory effect, induces apoptosis of cancer cells, and thus can be used as an effective immunotherapy candidate for solid cancers, a vaccine candidate for in-situ treatment of solid cancers, and a cancer-treating agent administered into tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Cancer vaccine composition comprising calcium lactate as an active ingredient and use thereof

[0001] The present invention relates to a pharmaceutical composition comprising calcium lactate as an active ingredient and its use, and more particularly, to a cancer vaccine composition comprising calcium lactate as an active ingredient and its use.

[0002] Current cancer treatments typically involve systemic chemotherapy with non-targeted small molecules or antibody-specific cytotoxic agents that preferentially enter or bind to cancer cells (in the case of antibody-specific agents) by various mechanisms and kill them.

[0003] Systemic chemotherapy can reach many distant metastatic sites, except brain metastases, but in too many patients, responses are usually short-lived (months to years) and ultimately result in tumor recurrence.

[0004] Immunological approaches are rapidly gaining traction in cancer treatment paradigms, as the body's natural immune system can destroy cancer cells after recognition. However, some cancer cells, and even cancer stem cells, can initially evade immune surveillance, acquire the ability to evolve, and ultimately survive by remaining relatively immune-invisible [Gaipi et al, Immunotherapy 6:597-610, 2014].

[0005] One possible mechanism by which traditional vaccine adjuvants, such as alum, enhance immune responses is through the release of DAMPs. Adjuvants, such as alum, can promote Th2 responses and induce the release of host cell DNA, which can induce T cell responses and the production of IgG1 and IgE. Ideally, adjuvants should be molecularly defined and enhance the magnitude and duration of antigen-specific immune responses, providing protection against intracellular pathogens and / or reducing tumor burden.

[0006] Activation of the STING (Stimulator of Interferon Genes) protein can produce an activated or primed immune system similar to that produced by an adjuvant. This can create a protective or preventive state upon challenge or re-challenge by intracellular pathogens or viruses, or by suppressing the growth or proliferation of intracellular pathogens or tumors.

[0007] It is also recognized that when a STING activator is therapeutically administered to a system in which a tumor or pathogen is present, it may act beneficially in two different, yet related, ways. First, as described above, by direct suppression of tumor / pathogen eradication through upregulation of type I interferons and cytokines, thereby directly acting against the tumor / pathogen. Second, a STING activator will also induce a sustained immune response, such that re-challenge or re-inoculation with the pathogen or tumor can be resisted through both general activation of the immune system and potential antigen-specific responses to the pathogen or tumor.

[0008] Meanwhile, necroptosis is a programmed form of necrosis or inflammatory cell death mechanism. Since its first name in 2005, key factors related to it, such as RIPK3 (receptor-interacting protein kinase 3), have been identified since 2009.

[0009] Necroptosis, which causes cell membrane rupture, is characterized by a stronger immune response than immunogenic cell death induced by conventional chemotherapy or the emerging photodynamic therapy. This is because it does not involve intracellular protein degradation or oxidation, allowing damage-associated molecular patterns (DAMPs) and tumor antigens, which lose their immunogenicity during this process, to be released in their original immunogenic state, effectively inducing an anticancer immune response. Due to these characteristics, necroptosis was expected to amplify the responsiveness to existing anticancer treatments, maximizing their therapeutic efficacy.

[0010] However, although tumor necrosis factor cytokines including TRAIL, pan-caspase inhibitors including zVAD, and MLKL interfering RNA were developed, their efficacy was limited.

[0011] Therefore, since the clinical application of current anticancer treatment through necroptosis is limited, there is a need to develop a necroptosis-inducing agent that selectively acts on cancer cells.

[0012] The present invention has been conceived to solve the above problems and meet the above needs, and the purpose of the present invention is to provide a novel pharmaceutical composition.

[0013] Another object of the present invention is to provide a novel cancer treatment or cancer vaccine composition.

[0014] Another object of the present invention is to provide a novel method for treating or preventing cancer.

[0015] In order to achieve the above purpose, the present invention comprises: a) calcium lactate and

[0016] b) A pharmaceutical composition is provided comprising, as an active ingredient, at least one substance selected from the group consisting of phosphate, stem cells, cytokines, cancer cell lines, antigens derived from the cancer cell lines, polynucleotides encoding the antigens, antigen gene constructs in which the polynucleotides are operably linked to a promoter, and expression vectors including the gene constructs.

[0017] In one embodiment of the present invention, the cancer cell line-derived antigen is a tumor specific antigen (TSA) or a tumor associated antigen (TAA), the cytokine is at least one cytokine selected from the group consisting of IL-2, IL-7, IL-12, IL-15, IL-21, and GM-CSF, and the phosphate is preferably monosodium phosphate, but is not limited thereto.

[0018] In another embodiment of the present invention, the composition preferably further comprises a carbonate, but is not limited thereto.

[0019] In another embodiment of the present invention, in the composition, the calcium lactate is preferably 2.5 mM to 54 mM, and the phosphate is preferably 5 mM or more, but is not limited thereto.

[0020] In addition, the present invention provides a pharmaceutical composition for treating cancer, comprising as an active ingredient at least one substance selected from the group consisting of a) calcium lactate and b) phosphate, stem cells, cytokines, cancer cell lines, antigens derived from the cancer cell lines, polynucleotides encoding the antigens, antigen gene constructs in which the polynucleotides are operably linked to a promoter, and expression vectors comprising the gene constructs.

[0021] In one embodiment of the present invention, the cancer cell line-derived antigen is a tumor specific antigen (TSA) or a tumor associated antigen (TAA), the cytokine is at least one cytokine selected from the group consisting of IL-2, IL-7, IL-12, IL-15, IL-21, and GM-CSF, and the phosphate is preferably monosodium phosphate, but is not limited thereto.

[0022] In another embodiment of the present invention, the composition preferably further comprises a carbonate, but is not limited thereto.

[0023] In another embodiment of the present invention, in the composition, the calcium lactate is preferably 2.5 mM to 54 mM, and the phosphate is preferably 5 mM or more, but is not limited thereto.

[0024] In another embodiment of the present invention, the cancer is preferably selected from the group consisting of colorectal cancer, lung cancer, stomach cancer, glioma, liver cancer, melanoma, kidney cancer, urothelial cancer, head and neck cancer, Merkel cell carcinoma, prostate cancer, blood cancer, breast cancer, colon cancer, rectal cancer, pancreatic cancer, brain cancer, ovarian cancer, bladder cancer, bronchial cancer, skin cancer, cervical cancer, endometrial cancer, esophageal cancer, thyroid cancer, bone cancer, and combinations thereof, but is not limited thereto.

[0025] In addition, the present invention provides a cancer vaccine composition comprising, as an active ingredient, at least one substance selected from the group consisting of a) calcium lactate and b) phosphate, stem cells, cytokines, cancer cell lines, antigens derived from the cancer cell lines, polynucleotides encoding the antigens, antigen gene constructs in which the polynucleotides are operably linked to a promoter, and expression vectors comprising the gene constructs.

[0026] In one embodiment of the present invention, the cancer cell line-derived antigen is a tumor specific antigen (TSA) or a tumor associated antigen (TAA), the cytokine is at least one cytokine selected from the group consisting of IL-2, IL-7, IL-12, IL-15, IL-21, and GM-CSF, and the phosphate is preferably monosodium phosphate, but is not limited thereto.

[0027] In another embodiment of the present invention, the composition preferably further comprises a carbonate, but is not limited thereto.

[0028] In another embodiment of the present invention, in the composition, the calcium lactate is preferably 2.5 mM to 54 mM, and the phosphate is preferably 5 mM or more, but is not limited thereto.

[0029] In another embodiment of the present invention, the composition is preferably administered intratumoral, but is not limited thereto.

[0030] In another embodiment of the present invention, the cancer is preferably selected from the group consisting of colorectal cancer, lung cancer, stomach cancer, glioma, liver cancer, melanoma, kidney cancer, urothelial cancer, head and neck cancer, Merkel cell carcinoma, prostate cancer, blood cancer, breast cancer, colon cancer, rectal cancer, pancreatic cancer, brain cancer, ovarian cancer, bladder cancer, bronchial cancer, skin cancer, cervical cancer, endometrial cancer, esophageal cancer, thyroid cancer, bone cancer, and combinations thereof, but is not limited thereto.

[0031] In addition, the present invention provides a method for treating or preventing cancer, comprising administering to a subject having a cancer a composition comprising, as an active ingredient, at least one substance selected from the group consisting of a) calcium lactate and b) phosphate, stem cells, cytokines, cancer cell lines, antigens derived from the cancer cell lines, polynucleotides encoding the antigens, antigen gene constructs in which the polynucleotides are operably linked to a promoter, and expression vectors comprising the gene constructs.

[0032] In one embodiment of the present invention, the cancer cell line-derived antigen is a tumor specific antigen (TSA) or a tumor associated antigen (TAA), the cytokine is at least one cytokine selected from the group consisting of IL-2, IL-7, IL-12, IL-15, IL-21, and GM-CSF, and the phosphate is preferably monosodium phosphate, but is not limited thereto.

[0033] In another embodiment of the present invention, the composition preferably further comprises a carbonate, but is not limited thereto.

[0034] In another embodiment of the present invention, in the composition, the calcium lactate is preferably 2.5 mM to 54 mM, and the phosphate is preferably 5 mM or more, but is not limited thereto.

[0035] In another embodiment of the present invention, the composition is preferably administered intratumoral, but is not limited thereto.

[0036] In another embodiment of the present invention, the cancer is preferably selected from the group consisting of colorectal cancer, lung cancer, stomach cancer, glioma, liver cancer, melanoma, kidney cancer, urothelial cancer, head and neck cancer, Merkel cell carcinoma, prostate cancer, blood cancer, breast cancer, colon cancer, rectal cancer, pancreatic cancer, brain cancer, ovarian cancer, bladder cancer, bronchial cancer, skin cancer, cervical cancer, endometrial cancer, esophageal cancer, thyroid cancer, bone cancer, and combinations thereof, but is not limited thereto.

[0037] The present invention is further described below.

[0038] The composition of the present invention is a pharmaceutical composition, and includes, in addition to the calcium lactate described above, a pharmaceutically acceptable excipient or carrier.

[0039] The term "pharmaceutically acceptable" as used herein refers to properties and / or substances that are acceptable to the patient from a pharmacological / toxicological standpoint with respect to composition, formulation, safety, patient tolerability, and bioavailability, and are acceptable to the compounding pharmacist from a physical / chemical standpoint. A "pharmaceutically acceptable carrier" refers to a medium that does not interfere with the biological activity of the active ingredient(s) and is nontoxic to the host upon administration.

[0040] The subject of application of the pharmaceutical composition of the present invention may be any animal, and specifically, mammals such as humans, mice, rats, hamsters, guinea pigs, rabbits, cats, dogs, monkeys, cows, horses, pigs, etc. The most preferred subject is humans.

[0041] The pharmaceutical composition of the present invention may be formulated as a freeze-dried or liquid preparation using any suitable means known in the art. Non-limiting examples of liquid preparations include solutions, suspensions, syrups, slurries, and emulsions. Suitable liquid carriers include any suitable organic or inorganic solvent, such as water, alcohol, saline, buffered saline, physiological saline, dextrose solution, propylene glycol solution, and the like, preferably in sterile form.

[0042] The pharmaceutical composition of the present invention may be formulated in neutral or salt form. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of the active polypeptide), which are formed with inorganic acids such as hydrochloric acid or phosphoric acid, or organic acids such as acetic acid, oxalic acid, tartaric acid, mandelic acid, and the like. In addition, salts formed from the free carboxyl groups may be derived from inorganic bases such as sodium, potassium, ammonium, calcium, or ferric hydroxides, and organic bases such as isopropylamine, trimethylamine, 2-ethylaminoethanol, histidine, procaine, and the like.

[0043] The pharmaceutical composition of the present invention is preferably formulated for inoculation or injection into a subject. For injection, the composition of the present invention may be formulated in an aqueous solution, such as water or alcohol, or in a physiologically compatible buffer, such as Hanks' solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory agents, such as suspending agents, preservatives, stabilizers, and / or dispersing agents. In addition, the injection formulation may be prepared as a solid form preparation that is converted to a liquid form preparation suitable for injection immediately prior to use, for example, by reconstitution with a suitable vehicle, such as sterile water, saline, or alcohol, prior to use.

[0044] Additionally, the compositions of the present invention may be formulated as delayed-release vehicles or depot preparations. Such long-acting formulations may be administered by inoculation or implantation (e.g., subcutaneously or intramuscularly), or by injection.

[0045] The compositions of the present invention may be administered by infusion or injection (e.g., intravenously, intramuscularly, intradermally, subcutaneously, intrathecally, intraduodenal, intraperitoneally, etc.). Furthermore, the compositions of the present invention may be administered intranasally, vaginally, rectally, orally, or transdermally. Additionally, the compositions of the present invention may be administered using a "needle-free" delivery system. Preferably, the compositions are administered by intradermal injection. Administration may be as directed by a physician or healthcare assistant.

[0046] The injection may be divided into multiple injections, and these divided doses are preferably administered substantially simultaneously. When administered in divided doses, the dose of the immunogen is preferably, but not necessarily, equally distributed among each separate injection. If an adjuvant is present in the vaccine composition, the dose of the adjuvant is preferably, but not necessarily, equally distributed among each separate injection. The divided injections for divided doses are, in some embodiments, administered substantially adjacent to each other in the patient's body.

[0047] A variety of alternative pharmaceutical delivery systems may be utilized. Non-limiting examples of such systems include liposomes and emulsions. Certain organic solvents, such as dimethyl sulfoxide, may also be used. Additionally, the compositions of the present invention may be delivered using delayed-release systems, such as a semipermeable matrix of solid polymers containing the therapeutic agent. Various available delayed-release materials are well known to those skilled in the art. Depending on their chemical properties, delayed-release capsules can release the vaccine composition over a period ranging from several days to several weeks to several months.

[0048] To prevent cancer recurrence in a patient in remission, a therapeutically effective amount of a composition of the present invention is administered to the subject. A therapeutically effective amount, as measured by any means suitable in the art, will provide a clinically significant increase in the number of tumor-associated antigen-specific cytotoxic T-lymphocytes (CD8+) and a clinically significant increase in the cytotoxic T-lymphocyte response to the antigen in the patient. Typically, the therapeutically effective amount of the vaccine composition will destroy any remaining microscopic disease in the patient, thereby significantly reducing or eliminating the risk of cancer recurrence in the patient.

[0049] The effective dose of a composition of the present invention may depend on many variables, including, but not limited to, race, breed, size, height, weight, age, the overall health of the patient, the type of formulation, the mode or method of administration, or the presence or absence of risk factors that significantly increase the likelihood that the cancer will recur in the patient. Such risk factors include, but are not limited to, the type of surgery, the status and number of positive lymph nodes, the size of the tumor, the histologic grade of the tumor, the presence / absence of hormone receptors (estrogen and progesterone receptors), HER2 / neu expression, lymphovascular invasion, and genetic predisposition (such as BRCA 1 and 2). In some preferred embodiments, the effective dose depends on whether the patient is lymph node positive or lymph node negative, and if the patient is lymph node positive, the number and extent of positive lymph nodes. In all cases, a suitable effective dose can generally be determined by one skilled in the art using routine optimization techniques and the skilled and informed judgment of a professional and other factors apparent to one of ordinary skill in the art. Preferably, a therapeutically effective amount of a vaccine composition described herein will provide a therapeutic prophylactic benefit without causing substantial toxicity to the subject.

[0050] The toxicity and therapeutic efficacy of the compositions of the present invention can be measured using standard pharmaceutical procedures in cell cultures or experimental animals, for example, to determine the LD50 (the dose lethal to 50% of a population) and the ED50 (the dose therapeutically effective in 50% of a population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD50 / ED50. Compositions that exhibit a large therapeutic index are preferred. Data obtained from cell culture assays and animal studies can be used to formulate a range of dosages for use in patients. The dosage of such compositions preferably falls within a range of circulating concentrations that includes the ED50 with little or no toxicity. The dosage may vary within this range depending on the dosage form employed and the route of administration utilized.

[0051] The dosage for preventing recurrent cancer will vary depending on, among other factors, the severity of the patient's condition, the relative risk of recurrence, and the route of administration. The severity of the patient's condition can be assessed, for example, in part by standard prognostic assessment methods.

[0052] The vaccine composition of the present invention may be administered to a patient on any suitable schedule to induce and / or support protective immunity against cancer recurrence, or to induce and / or support a cytotoxic T lymphocyte response. For example, after administering the vaccine composition described and exemplified herein to a patient as a primary vaccination, a booster may be administered to support and / or maintain protective immunity. In some embodiments, the vaccine composition may be administered to a patient once, twice, or more times per month.

[0053] The vaccine administration schedule, including primary and booster shots, may continue for as long as the patient requires, for example, over the course of several years, to extend the patient's lifespan. In some cases, the vaccine schedule includes more frequent administrations at the beginning of the vaccine regimen, followed by less frequent administrations (e.g., boosters) during the period of time necessary to maintain protective immunity.

[0054] The vaccine composition may be administered at a lower dose at the beginning of the vaccine regimen, with higher doses administered over time. Furthermore, the vaccine may be administered at a higher dose at the beginning of the vaccine regimen, with lower doses administered over time. The frequency of primary and booster doses, as well as the dose of antigen administered, may be tailored and / or adjusted to meet the specific needs of each individual patient, as determined by the attending physician using any method suitable in the art.

[0055] In one embodiment of the present invention, the vaccine composition is for treating and preventing cancer.

[0056] As used herein, the term "prevention" refers to any success or indication of success in preventing the recurrence / relapse of cancer in a patient in clinical remission, as measured by any objective or subjective variable, including the results of radiological or physical examinations.

[0057] The term 'METI-101' used in the specification and / or drawings of the present invention means calcium lactate.

[0058] The calcium lactate of the present invention can act as an agonist of STING by increasing the expression of STING, an immune activation inducer inside tumor cells, and at the same time causing STING activation, and it can induce an anti-tumor immune response through the activation of the immune system as well as have an effect on secondary immunity, and it was confirmed as a result of a re-challenge experiment that it has an anti-tumor immune memory effect.

[0059] The composition of the present invention can be used as an effective solid cancer immunotherapy candidate substance, an in situ cancer treatment vaccine candidate substance, and an intratumoral treatment agent by inducing apoptosis of cancer cells.

[0060] Figure 1 is a diagram showing the comparison of the cell death patterns and cell-specific effects of human cancer cell lines by METI-101 (#p<0.0001 vs Control, NS Not Significant).

[0061] Figure 2 shows the ratio of the cell death effect of human cancer cell lines by METI-101 (***p<0.001 vs Control, #p<0.0001 vs Control, NS Not Significant).

[0062] Figure 3 is a drawing showing the confirmation of necroptosis factor expression by Meti-101.

[0063] Figure 4 shows the quantitative analysis of STING and activated STING induced by Meti-101 (***p<0.001 vs Control, #p<0.0001 vs Control).

[0064] Figure 5 is a graph showing the mRNA expression levels of Interferon α and β by METI-101 in human cancer cell lines (**p<0.005 vs Control, ***p<0.001 vs Control, #p<0.0001 vs Control).

[0065] Figure 6 is a diagram showing the stimulation of interferon receptor synthesis in human cancer cell lines by Meti-101 (**p<0.005 vs Control, ***p<0.001 vs Control, #p<0.0001 vs Control).

[0066] Figure 7 shows the change in IRF7, which transmits the signal of type I interferon, and the increase in MHC1 in human cancer cell lines (*p<0.01 vs Control, ***p<0.001 vs Control, #p<0.0001 vs Control).

[0067] Figure 8 shows the change in the expression level of chemokine, an immune response inducer, by Meti-101 treatment in human cancer cells (**p<0.005 vs Control, ***p<0.001 vs Control, #p<0.0001 vs Control).

[0068] Figure 9 shows the decrease in CD24 and CD47 of human cancer cell lines by Meti-101 treatment (**p<0.005 vs Control, ***p<0.001 vs Control).

[0069] Figure 10 is a drawing showing the inhibition of angiogenesis in HUVEC cells by inhibition of VEGF production.

[0070] Figure 11 is a diagram showing the differentiation of fibroblasts by TGF-β treatment and the differentiation inhibitory effect of Meti-101.

[0071] Figure 12 is a drawing showing the reduction in TGF-β secretion of human cancer cell lines by Meti-101.

[0072] Figure 13 is a diagram showing the change in intracellular lactate concentration and pH concentration (* <p<0.01 vs Control, **p<0.005 vs Control),

[0073] Figure 14 is a diagram showing the analysis of PD-L1 expression in A549 and H1975 lung cancer cell lines.

[0074] Figure 15 shows the histological analysis of VEGF changes and CD31 in the tumor (**p<0.005 vs Control).

[0075] Figure 16 is a drawing showing the evaluation of the cancer growth inhibition effect of combined administration of MSC and Meti-101 in a xenograft mouse model using the mouse colon cancer cell line MC-38.

[0076] Figure 17 is a comparative diagram showing the confirmation of immune memory effect using MC-38 cell line (*p<0.01 vs Control).

[0077] Figure 18 is a diagram showing changes in white pulp in the mouse spleen.

[0078] Figure 19 is a diagram showing the immune distribution according to tumor size and white pulp size.

[0079] Figure 20 is a diagram showing the confirmation of co-administration of peptide vaccine and Meti-101 in a lung cancer cell animal model using the TC-1 cell line.

[0080] Figure 21 is a diagram showing the confirmation of antitumor evaluation in the MC-38 animal model by combined administration of IL-7 and Meti-101.

[0081] Figures 22 to 24 are photographs of cells cultured in RPMI1640 medium containing 10% FBS (Figure 22), serum-free RPMI1640 medium (Figure 23), and serum-free RPMI1640 medium (Figure 24) treated with calcium lactate.

[0082] Figure 25 is a photograph showing the apoptotic necrosis-inducing effect of calcium lactate on HCT-116 colon cancer cell line cultured in serum-free RPMI1640 medium.

[0083] Figure 26 is a graph showing the cell survival rate of HCT-116 cells cultured in serum-free RPMI1640 medium and cells cultured in serum-free RPMI1640 medium treated with calcium lactate.

[0084] Figure 27 is a photograph of HCT-116 colon cancer cells cultured in serum-free DMEM, IMEM, and RPMI1640 media with calcium lactate added.

[0085] Figure 28 is a graph comparing the survival rates of colon cancer cells in serum-free DMEM, IMEM, and RPMI1640 media treated with calcium lactate.

[0086] Figure 29 is a graph confirming protein factors related to immune induction in cancer cells when apoptosis necrosis of cancer cells is induced with METI-101, Figure 30 is a photograph confirming immune markers and signaling core proteins of cancer cells undergoing apoptosis necrosis by immunoblotting, and Figure 31 is a graph confirming the expression level of interferon at the mRNA level.

[0087] Figure 32 is a graph confirming the TSPAN8 protein, a type of tumor-associated antigen, through enzyme-linked immunosorbent assay, and Figure 33 is a graph confirming the CA9 protein, a type of tumor marker, through enzyme-linked immunosorbent assay.

[0088] Figure 34 shows the results of measuring the amount of nucleic acids released from cells when cells are damaged and die, and Figure 35 shows the results of measuring the amount of representative cell damage proteins released from cells when cells are damaged and die.

[0089] Figure 36 is a photograph showing that apoptosis was induced in a tumor grown by xenografting the human cancer cell line HCT116 into a mouse by direct intratumoral injection of METI-101, and that the marker, active MLKL, was stained using immunohistochemistry.

[0090] Figure 37 is a photograph showing a tumor grown by xenografting the human cancer cell line HCT116 into a mouse, in which METI-101 was directly injected into the tumor to induce apoptosis and necrosis, and the distribution of lymphocytes within the tumor was confirmed using hematoxylin-eosin staining.

[0091] Figure 38 is a schematic diagram of an animal experiment to confirm that cancer vaccination is induced through standard treatment, radiation therapy, and intratumoral injection of METI-101.

[0092] Figure 39 is a graph showing the frequency of tumor formation when cancer cells were re-administered with radiation therapy and intratumoral injection of METI-101.

[0093] Figure 40 is a photograph of cells in which apoptosis was induced by METI-101 in a NaH2PO4+ NaHCO3 solution, which is a condition showing the same phenomenon as apoptosis using Welgene's RPMI1640 medium, and Figure 41 is the result of measuring apoptosis and turbidity by METI-101 in a NaH2PO4+ NaHCO3 solution compared to Welgene's RPMI1640 medium.

[0094] The present invention is described in more detail below through non-limiting examples. However, the following examples are intended to illustrate the present invention, and the scope of the present invention is not to be construed as being limited by the following examples.

[0095] Example 1. Apoptosis-induced cell death in various cancer cells

[0096] Quantification of immune-induced cytotoxic substances (DAMPs)

[0097] The main ingredient, calcium lactate pentahydrate, was quantified for its production of damage-inducing substances (DAMPs), which are immune-stimulating molecules. DAMP activation was confirmed to induce selective immune-induced cell death in human cancer cell lines. To demonstrate this, human cancer cells, mouse cancer cells, and normal human fibroblast cells were compared.

[0098] Human colon cancer (HCT-116), pancreatic cancer (AsPC-1), and breast cancer (MDA-MB-231) cell lines and mouse colon cancer (MC-38, CT-26) cell lines were seeded at 3.5 x 10 in 60 mm cell culture dishes.5 Cells were seeded at a number of 10 cells / well. As a control, a cell line (MRC-5) derived from fetal lung tissue was used and seeded under the same conditions as cancer cells. After seeding, the cells were cultured for 24 hours at 37°C and 5% CO2 to stabilize them. The stabilized cells were washed with PBS to remove FBS and then cultured for 22 hours under normoxic conditions (37°C and 5% CO2) and hypoxic conditions (37°C and 5% CO2, 1% O2) in FBS-free medium. The cultured cells were washed with PBS and treated with Meti-101 at a concentration of 2.5 mM in FBS-free medium for 2 hours. Afterwards, cell images were obtained through a microscope, and an aliquot of the cell culture was taken and the absorbance at a wavelength of 660 nm was measured using a spectrophotometer.

[0099] Cell observation results showed that human cancer cells treated with 2.5 mM Meti-101 did not show normal cell morphology, and it was confirmed that cell byproducts were introduced into the medium, which increased the absorbance of the medium at a wavelength of 660 nm (p<0.0001). In the case of mouse cancer cells, the effect of Meti-101 was relatively smaller than that of human cancer cells, and it was confirmed that cell death due to Meti-101 hardly occurred in normal cells other than cancer cells. These results confirmed that Meti-101 is an effective anticancer agent that significantly induces apoptosis in human cancer cells while minimizing damage to normal cells (Fig. 1).

[0100] Quantification of immune-induced apoptosis

[0101] To confirm that the main ingredient, calcium lactate pentahydrate, selectively induces immune-induced apoptosis in human cancer cell lines, colon cancer, pancreatic cancer, breast cancer, and lung cancer were selected, and mouse colon cancer was used as a control group.

[0102] Human colon cancer (HCT-116), pancreatic cancer (AsPC-1), non-small cell lung cancer (H1299), and breast cancer (MDA-MB-231) cell lines and mouse colon cancer (MC-38, CT-26) cell lines were seeded at 3.5 x 10 in 60 mm cell culture dishes. 5 Cells were seeded at a number of 10 cells / well. After seeding, the cells were cultured for 24 hours at 37°C and 5% CO2 to stabilize them. The stabilized cells were washed with PBS to remove FBS and then cultured for 22 hours under normoxic conditions (37°C and 5% CO2) and hypoxic conditions (37°C and 5% CO2, 1% O2) in FBS-free medium. The cultured cells were washed with PBS and treated with Meti-101 at a concentration of 2.5 mM in FBS-free medium for 2 hours. After incubation, the cells were detached with trypsin, collected in a conical tube, and centrifuged to sediment the cells. The supernatant was discarded, resuspended in medium, and 10 μl was taken and the number of viable cells was counted using a hemocytometer.

[0103] In human cancer cell lines, Meti-101 treatment induced cell death, with no viable cells being detected. However, in mouse cancer cell lines, Meti-101 significantly induced cell death, although it did not induce cell death as it did in human cancer cell lines. Based on this, we confirmed that Meti-101 acts specifically on cancer cells and can specifically trigger immune-induced apoptosis in human cancer cell lines (Fig. 2).

[0104] Identification of factors associated with cell death due to immune-induced necroptosis

[0105] To confirm necroptosis, a type of cell death, changes in RIP1, p-RIP1, RIP3, p-RIP3, MLKL, and p-MLKL were observed. The changes were confirmed by immunomagnetic fluorescence (WB) using intracellular proteins in human colon, pancreatic, lung, and breast cancer cell lines.

[0106] Human colon cancer (HCT-116), pancreatic cancer (AsPC-1), lung cancer (H1299), and breast cancer (MDA-MB-231) cell lines were seeded at 3.5 x 10 in each 60 mm cell culture dish. 5 Cells were seeded at a number of 10 cells / well. After seeding, the cells were cultured for 24 hours at 37°C and 5% CO2 to stabilize them. The stabilized cells were washed with PBS and cultured for 1 hour in RPMI-1640 medium containing 0% FBS and 2.5 mM Meti-101 under low-oxygen conditions (37°C, 5% CO2, 1% O2). The cultured cells were collected with RIPA buffer and proteins were extracted. The extracted proteins were quantified using a protein assay, separated by size, and then RIP1, p-RIP1, RIP3, p-RIP3, MLKL, and p-MLKL-specific antibodies were attached to the proteins to determine the degree of protein fluorescence, thereby comparing the expression levels of activated proteins related to necroptosis by Meti-101 in cancer cells.

[0107] Experimental results showed that Meti-101 reduced the expression of RIP1, RIP3, and MLKL, which are necroptosis-related factors, and simultaneously reduced the activation of p-RIP1, p-RIP3, and p-MLKL. This suggests that Meti-101 induces necroptosis, a type of cell death (Fig. 3).

[0108] Example 2. Confirmation of induction of antitumor immune activity

[0109] Identification of tumor-intrinsic immune activation inducer STING and signal transduction

[0110] To confirm the induction of an antitumor immune response by calcium lactate pentahydrate, we observed changes in STING, an immune activation inducer within tumor cells. Using human colon and pancreatic cancer cell lines, we confirmed the induction of STING, a response factor to dsDNA, an intracellular DAMP, and activated STING by immunomagnetic spectroscopy (WB).

[0111] Human colon cancer (HCT-116) and pancreatic cancer (AsPC-1) cell lines were seeded at 3.5x10 in 60mm cell culture dishes, respectively. 5 Cells were seeded at a number of 10 cells / well. After seeding, the cells were cultured for 24 hours at 37°C and 5% CO2 to stabilize them. The stabilized cells were washed with PBS and cultured for 24 hours at low oxygen conditions (37°C, 5% CO2, 1% O2) in RPMI-1640 medium containing 10% FBS and 2.5 mM Meti-101. The cultured cells were collected with RIPA buffer and proteins were extracted. The extracted proteins were quantified using a protein assay, separated by size, and then STING-specific antibodies were attached to determine the degree of protein fluorescence, thereby comparing the protein expression levels of STING (Stimulator of Interferon Genes) and activated STING by Meti-101 in cancer cells.

[0112] Experimental results showed that Meti-101 increased the expression of STING, an immune-activating factor, within tumor cells, while simultaneously inducing STING activation. This suggests that Meti-101 can act as a STING agonist, inducing an anti-tumor immune response through immune system activation, as well as exerting effects on secondary immunity (Figure 4).

[0113] Confirmation of tumor-intrinsic immune activity Type I interferon production

[0114] To confirm the induction of antitumor immune responses by calcium lactate pentahydrate, the production of type I interferons (IFN-α) and IFN-β) produced by tumor cells was quantified. The amount of type I interferon mRNA induced by activated STING was quantified using RT-PCR in human colon, breast, and pancreatic cancer cell lines.

[0115] Human colon cancer (HCT-116), breast cancer (MDA-MB-231), and pancreatic cancer (AsPC-1) cell lines were seeded at 3.5 x 10 in 60 mm cell culture dishes. 5 Cells were seeded at a number of 10 cells / well. After seeding, the cells were cultured for 24 hours at 37°C and 5% CO2 to stabilize them. The stabilized cells were washed with PBS and cultured for 24 hours in RPMI-1640 medium containing 10% FBS and 2.5 mM Meti-101 under low-oxygen conditions (37°C, 5% CO2, 1% O2). mRNA was extracted from the cultured cells using Trizol. The mRNA was quantified to synthesize equal amounts of cDNA, and qRT-PCR was performed using Syber green and target primers to quantitatively compare the expression levels of type I interferon.

[0116] We confirmed that the mRNA expression of IFN-α and IFN-β, which belong to type I interferons, increased approximately 2.5 to 3 times by Meti-101. The increased interferon activates natural killer (NK) cells and macrophages, increasing the innate immune response, and promotes major histocompatibility complex (MHC) synthesis to present antigens on the cell surface. Therefore, the increase in type I interferon mRNA expression by Meti-101 suggests that immune cells recognize cancer cells as antigens and help them attack cancer cells smoothly (Figure 5).

[0117] Confirmation of expression of type I interferon receptors on the surface of tumor cells

[0118] To confirm the induction of an antitumor immune response by calcium lactate pentahydrate, we quantified the mRNA and protein expression levels of IFNAR1 and IFNAR2, type I interferon receptors produced by tumor cells. This was confirmed using RT-PCR and immunomagnetic spectroscopy (WB) in human colon, breast, and pancreatic cancer cell lines. This was done to determine the responsiveness of cancer cells to type I interferon.

[0119] Human colon cancer (HCT-116), pancreatic cancer (AsPC-1), and breast cancer (MDA-MB-231) cell lines were seeded at 3.5 x 10 each in 60 mm cell culture dishes. 5 Cells were seeded at a number of 10 cells / well. After seeding, the cells were cultured for 24 hours at 37°C, 5% CO2 for stabilization. The stabilized cells were washed with PBS and cultured for 24 hours in RPMI-1640 medium containing 10% FBS and 2.5 mM Meti-101 under low-oxygen conditions (37°C, 5% CO2, 1% O2). RIPA buffer was used to obtain proteins from the cultured cells, and mRNA was extracted using Trizol. The extracted proteins were quantified using a protein assay, separated by size, and then labeled with an Interferon receptor-specific antibody to determine the fluorescence intensity of the proteins. This was used to compare the protein expression levels of Interferon receptor 1 and Interferon receptor 2 induced by Meti-101 in cancer cells. Similarly, mRNA was quantified to synthesize the same amount of cDNA, and qRT-PCR was performed using Syber green and target primers to quantitatively compare the expression levels of Interferon receptors.

[0120] The experimental results showed that the expression of interferon receptor, a cell surface membrane protein, increased in human cancer cell lines treated with METI-101. The mRNA expression of IFNAR1 was significantly increased in human cancer cell lines, and the mRNA of IFNAR2 was also confirmed to increase by approximately 1.5 to 3 times. The protein expression of IFNAR1 and IFNAR2 was also increased by Meti-101 in three types of human cancer cells. The increase in interferon receptor strengthens the signaling strength of type I interferon, leading to the activation of STING, which can promote the anti-tumor immune response through a feedback mechanism (Fig. 6).

[0121] Confirmation of Type I interferon signaling on the surface of tumor cells

[0122] To confirm the immune response within tumor cells induced by calcium lactate pentahydrate, type I interferon signaling (IRF7, MHC I) was examined. This was confirmed using RT-PCR and immunomagnetic spectroscopy (WB) in human colon, breast, and pancreatic cancer cell lines. Through this, we aimed to confirm the increase in type I interferon signaling in cancer cells.

[0123] Human colon cancer (HCT-116 and HT29), pancreatic cancer (AsPC-1), and breast cancer (MDA-MB-231) cell lines were seeded at 3.5 x 10 in 60 mm cell culture dishes. 5Cells were seeded at a number of 10 cells / well. After seeding, the cells were cultured for 24 hours at 37°C, 5% CO2 for stabilization. The stabilized cells were washed with PBS and cultured for 24 hours in RPMI-1640 medium containing 10% FBS and 2.5 mM Meti-101 under low-oxygen conditions (37°C, 5% CO2, 1% O2). RIPA buffer was used to obtain proteins from the cultured cells, and mRNA was extracted using Trizol. The extracted proteins were quantified using a protein assay, separated by size, and then attached to an antibody specific for type I interferon signaling protein to determine the level of protein fluorescence. The protein expression levels of IRF-7 and MHC I induced by METI-101 in cancer cells were compared. Similarly, mRNA was quantified to synthesize the same amount of cDNA, and qRT-PCR was performed based on Syber green and target primers to quantitatively compare the level of IRF-7 mRNA expression.

[0124] Type I interferon signaling is mediated by IRF-7, and we confirmed that treatment with Meti-101 increased the mRNA and protein expression of IRF-7 in human cancer cell lines. As a result of signaling via IRF-7, we also confirmed that the protein expression of MHC1, a cell surface antigen presentation factor, increased (Fig. 7).

[0125] Confirmation of immune-induced chemokine expression by type I interferon signaling on the tumor cell surface

[0126] To confirm the immune response within tumor cells induced by calcium lactate pentahydrate, we examined the expression of immune-inducing chemokines. The mRNA and protein production of CXCL-9 and CXCL10 were determined using RT-PCR and WB in human colon, breast, and pancreatic cancer cell lines. This study aimed to confirm the increase in immune-inducing chemokines in cancer cells.

[0127] Human colon cancer (HCT-116), pancreatic cancer (AsPC-1), and breast cancer (MDA-MB-231) cell lines were seeded at 3.5 x 10 each in 60 mm cell culture dishes. 5 Cells were seeded at a number of 10 cells / well. After seeding, the cells were cultured for 24 hours at 37°C and 5% CO2 to stabilize them. The stabilized cells were washed with PBS and then cultured for 24 hours at low oxygen conditions (37°C, 5% CO2, 1% O2) in RPMI-1640 medium containing 10% FBS and 2.5 mM Meti-101. RIPA buffer was used to obtain proteins from the cultured cells, and mRNA was extracted using Trizol. The extracted proteins were quantified using a protein assay, separated by size, and then the fluorescence of the proteins was confirmed by attaching an antibody specific for type I interferon signaling proteins, thereby comparing the protein expression levels of CXCL-9 and CXCL-10 induced by Meti-101 in cancer cells. Similarly, mRNA was synthesized from the same amount of cDNA through quantitative analysis, and qRT-PCR was performed based on Syber green and target primers to quantitatively compare the level of mRNA expression of chemokines.

[0128] Experimental results confirmed that Meti-101 increases the secretion of chemokines, a type of immune-activating protein. In human cancer cell lines, the mRNA levels of CXCL-9 and CXCL-10 increased approximately 1.5- to 4.5-fold. In addition to chemokine mRNA, the protein levels of CXCL-10 also increased. Consequently, METI-101-treated human cancer cells induce an immune response, enabling the immune system to respond more sensitively to cancer cells (Figure 8).

[0129] Confirmation of tumor cell immune evasion factor expression

[0130] The immune response-inducing ability of calcium lactate pentahydrate was confirmed by measuring the reduction in immune evasion factors in tumor cells. The mRNA and protein production of CD24 and CD47 were determined using RT-PCR and immunomagnetic fluorescence (WB) in human colon, breast, and pancreatic cancer cell lines. This was done to confirm the increased immune reactivity of cancer cells.

[0131] Human colon cancer (HCT-116), pancreatic cancer (AsPC-1), and non-small cell lung cancer (H1299) cell lines were seeded at 3.5 x 10 in each 60 mm cell culture dish. 5Cells were seeded at a number of 10 cells / well. After seeding, the cells were cultured for 24 hours at 37°C and 5% CO2 to stabilize them. The stabilized cells were washed with PBS and cultured for 24 hours in RPMI-1640 medium containing 10% FBS and 2.5 mM Meti-101 under low-oxygen conditions (37°C, 5% CO2, 1% O2). RIPA buffer was used to obtain proteins from the cultured cells, and mRNA was extracted using Trizol. The extracted proteins were quantified using a protein assay, separated by size, and then specific antibodies were attached to immune evasion factor proteins to determine the level of protein fluorescence. This was used to compare the protein expression levels of CD24 and CD47 induced by Meti-101 in cancer cells. Similarly, mRNA was quantified to synthesize the same amount of cDNA, and qRT-PCR was performed using Syber green and target primers to quantitatively compare the levels of mRNA expression of immune evasion factors.

[0132] CD24 and CD47 are membrane proteins that enable immune evasion. We confirmed that Meti-101 treatment of human cancer cell lines significantly reduced CD24 and CD47 levels. All human cancer cell lines used in the experiment showed decreases in CD24 and CD47 mRNA and protein levels. Meti-101 treatment of human cancer cell lines eliminated anti-immune responses by downregulating CD24 and CD47, thereby increasing immune responsiveness to cancer cells (Figure 9).

[0133] Example 3. Confirmation of reduction in immunosuppressive factors and accessibility of immune cells in the tumor microenvironment.

[0134] Expression of angiogenic factor VEGF and inhibition of angiogenesis

[0135] We confirmed the inhibitory effect of calcium lactate pentahydrate on the expression of the immunosuppressive angiogenic factor VEGF in tumor cells (Fig. 12) and on the angiogenesis of vascular cells (Fig. 10). This is an immunosuppressive factor that inhibits the entry of immune cells into tumors. To confirm this, the expression level of the angiogenic factor VEGF mRNA was measured in two types of human colon cancer cells using RT-PCR (Fig. 12). In addition, the degree of angiogenesis was confirmed using human umbilical vein endothelial cells (HUVEC).

[0136] Human-derived colon cancer cells, HCT-116, were seeded at 3.5x10 in a 60mm cell culture dish. 5 Cells were seeded at a number of cells / well and cultured for 24 hours with 1% FBS to avoid interference from growth factors. After 24 hours of culture, 2.5 mM Meti-101 was treated to determine the drug effect. After 24 hours of treatment, cell culture media under normal culture conditions and Meti-101-treated conditions were collected using a centrifugal filter device (Millipore) (Conditioned Media, CM). Human umbilical vein endothelial cells (HUVEC) were seeded in 96-well culture plates and treated with cell culture media (CM). The following experiment used a tube formation assay kit (Cultrex), and dose-dependent changes in cell morphology were captured through fluorescence microscopy.

[0137] As a result, it was confirmed that angiogenesis occurred well in HUVECs not treated with Meti-101, but angiogenesis did not occur in HUVECs treated with Meti-101 (Fig. 10).

[0138] Inhibitory effects on the generation of tumor-active fibroblasts and fibrosis

[0139] We confirmed that differentiation into immunosuppressive fibroblasts was inhibited by quantifying the production of tumor-active fibroblasts that block immune cell entry into tumors and the extracellular matrix (ECM) and molecular biological markers produced by these cells. Experimentally, we confirmed that inhibition of rigid fibroblast formation on the tumor surface facilitates the entry of immune cells into tumors. To this end, we used two types of human fibroblasts to confirm their transformation into tumor-active fibroblasts, and the protein expression levels of various factors were determined by immunomagnetic blotting (WB).

[0140] Human normal lung cell lines (MRC-5 and WI-38) were seeded in 60 mm cell culture dishes at a density of 3.5 × 105 cells / well, respectively. After seeding, the cells were cultured for 24 h at 37°C and 5% CO2 for cell stabilization. For pretreatment, the cells were washed with PBS and cultured for an additional 8 h in DMEM medium containing 10% FBS and 5 ng / ml TGF-β. After pretreatment, the cells were treated with 5 ng / ml TGF-β and 2.5 mM Meti-101 in DMEM medium without FBS and cultured for 24 h under low-oxygen conditions (37°C, 5% CO2, 1% O2). The cultured cells were harvested with RIPA buffer and protein extraction was performed. The extracted proteins were quantified through protein assay, separated by size, and then the fluorescence level of the proteins was confirmed by attaching a fibrosis-related antibody, thereby comparing the protein expression levels of extracellular matrix and fibroblast differentiation by Meti-101 in cancer cells.

[0141] We confirmed that HIF-1α expression increased in fibroblasts under low oxygen conditions. Meti-101 reduces HIF-1α expression not only in cancer cells but also in fibroblasts under low oxygen conditions. When fibroblasts under low oxygen conditions were treated with TGF-β, phosphorylation of the TGF-β receptor and the signaling protein Smad2 was confirmed through protein immunoblotting. As a result, METI-101 decreased the phosphorylation of Smad2 and also decreased the TGF-β receptor on the cell surface. Similarly, it was found that hypoxia and TGF-β treatment in fibroblasts increased the expression of α-SMA, Col1a1, and Fibronectin, which are markers of fibrosis. Meti-101 can inhibit tumor fibrosis by dose-dependently reducing the synthesis of extracellular matrix proteins that induce fibrosis (Figure 11).

[0142] Confirmation of the inhibitory effect on the production of TGF-β, an immunosuppressive factor in cancer cells.

[0143] By confirming the production of TGF-β, which suppresses the activity of immune cells that attack cancer cells within tumors and enhances the activity of immunosuppressive immune cells, we confirmed the changes in the immunosuppressive tumor microenvironment induced by calcium lactate pentahydrate. To this end, we used human colon, lung, pancreatic, and breast cancer cells and confirmed the expression levels of TGF-β protein produced by these cancer cells by immunomagnetic spectroscopy (WB).

[0144] Human colon cancer (HCT-116), pancreatic cancer (AsPC-1), non-small cell lung cancer (H1975), and breast cancer (MDA-MB-231) cell lines were seeded at 3.5 x 10 in 60 mm cell culture dishes. 5 Cells were inoculated at a cell number of 10 cells / well. After inoculation, the cells were incubated at 37°C and 5% CO2 for 24 hours to stabilize the cells. 2 Cultured under conditions. Stabilized cells were washed with PBS and then cultured in RPMI-1640 medium containing 10% FBS and 2.5 mM Meti-101 under low oxygen conditions (37°C, 5% CO). 2, 1%O 2 ) were cultured for 24 hours. The cultured cells were collected with RIPA buffer and proteins were extracted. The extracted proteins were quantified through protein assay, separated by size, and then the fluorescence level of the protein was confirmed by attaching a specific antibody to TGF-β, thereby comparing the amount of TGF-β protein expression by Meti-101 in cancer cells.

[0145] Human cancer cell lines treated with Meti-101 showed a decrease in TGF-β protein synthesis. This decrease in TGF-β alters the tumor microenvironment, preventing immune cell dysfunction and allowing them to attack cancer cells normally (Figure 12).

[0146]

[0147] Confirmation of the inhibitory effect of cancer cells on the production of immunosuppressive chemicals

[0148] To confirm the production of lactate and protons, chemicals that suppress the activity of immune cells attacking cancer cells within tumors, we measured the concentration of intracellular lactate and changes in intracellular pH. For this purpose, we used the human colon cancer HCT-116 cell line and performed fluorescence cell analysis, enzymatic lactate quantitation, and pH measurement using dyes. Through these results, we confirmed the inhibitory effect of calcium lactate pentahydrate on the production of immunosuppressive chemicals.

[0149] To measure the concentration of intracellular lactate, 5 x 10 HCT-116 cells were cultured. 5Cells were seeded into 60 mm cell culture dishes at a concentration of 10 cells / well and cultured at 37°C for 24 hours. After culture, cells were treated with Meti-101 in RPMI1640 medium for 24 hours. Cells were then washed and collected with DPBS, and the cells and culture medium were homogenized and protein extracted. The protein concentration of the extracted protein was measured using the BCA assay. Lactate concentration was measured spectrophotometrically and normalized to total protein. The sample solution was incubated with the reagent for 30 minutes at room temperature. The absorbance of the sample was then measured at 450 nm using a microplate spectrophotometer. The above experiment was analyzed and performed using the Lactate Assay Kit (Abcam). Samples for measuring intracellular pH concentration were collected using the same method as above. The collected samples were cultured using the pH-sensitive pHrodo™ Red AM (Molecular Probes; Thermo Fisher Scientific). After incubation, fluorescence was measured and analyzed at a wavelength of 555–580 nm and converted to intracellular pH concentration using a nigericin calibration curve.

[0150] As a result, it was found that the concentration of intracellular lactate significantly increased when treated with Meti-101, and it was confirmed that the intracellular pH concentration significantly decreased under conditions treated with Meti-101 (Fig. 13).

[0151] Confirmation of the effect of suppressing the expression of immunosuppressive immune checkpoint proteins in cancer cells.

[0152] We measured the expression levels of immunosuppressive immune checkpoint proteins, which are expressed on the surface of cancer cells and block the tumor attack of immune cells, and induce immune cell death and fatigue. The amount of PD-L1, a representative immune checkpoint protein, was confirmed by immunofluorescence in human lung cancer cells expressing the normal and mutant forms of EGFR, and through this, the inhibitory effect of calcium lactate pentahydrate on the production of immunosuppressive immune checkpoint proteins was confirmed.

[0153] 3x10 human lung cancer cells A549 (EGFR wild type) and H1975 (EGFR mutant type) were cultured on bio-coated cover slips. 3 After inoculation, when cancer cells were stably established, 2.5 mM Meti-101 was treated and cultured for 24 hours under normoxic and hypoxic conditions (37℃, 5% CO2, 1% O2). After culture, each cell was fixed using a formalin solution, then bound with a PD-L1 antibody and fluorescence was expressed using a secondary antibody. After this process, the cells were mounted on a slide and observed using a confocal microscope at a wavelength of 570-620 nm.

[0154] In A549 and H1975 lung cancer cell lines, cells treated with Meti-101 showed a significant decrease in PD-L1 compared to untreated cells under both normoxic and hypoxic conditions (Fig. 14).

[0155] Example 4. In vivo immunopharmacological effects

[0156] Inhibition of intratumoral immunosuppressive VEGF expression and angiogenesis in a colon cancer transplantation model

[0157] In a xenograft model using human-derived cells, HCT-116, the tumor was extracted at autopsy after the experiment was completed. The extracted tumor was cut in half, and one half was fixed in formalin, and the other half was homogenized in RIPA buffer, and proteins were extracted and quantified using the BCA method. The extracted proteins were subjected to immunomagnetic banding (WB) experiments using an electroporation device, and the bands were quantified and data was converted into representative images using the ImmageJ program. The fixed tumor was cryosectioned after making a paraffin block, and slides were made. The prepared slides were stained with hematoxylin and eosin (H&E) using a CD31 antibody and immunofluorescence was performed.

[0158] As a result, it was found that tumor cells were significantly reduced in mice treated with Meti-101 (H&E), and the immunofluorescence results confirmed that CD31 was significantly reduced (Fig. 15).

[0159] Anticancer immunity and immune memory effects through combination with mesenchymal stem cells (MSCs)

[0160] 1) Confirmation of antitumor activity through combination with mesenchymal stem cells (MSCs)

[0161] To explore the pharmacological effects of Meti-101, a xenograft model was prepared using MC-38, a mouse-derived colon cancer cell line, divided into three groups: control group (10 mice), mesenchymal stem cell group (10 mice), and combined administration of mesenchymal stem cells and Meti-101 (10 mice). 1x10 MC-38 cell line was injected into the flank of the mouse. 5 was administered subcutaneously, and from the 7th day after tumor cell administration until the end of the experiment, tumor occurrence was confirmed (palpated) twice a week and the long and short axis sizes of the tumors were measured using an electric caliper.

[0162] Tumor size (mm) 3) = (long axis) x (short axis 2 ) / 2

[0163] Mesenchymal stem cells were administered intratumorally, 1 x 10, 5 times twice a day for a total of 3 days. 6 Cells were inoculated, and Meti-101 was injected subcutaneously at 20 mg / kg twice daily. After 10 days of administration, tumor size was significantly reduced in the mesenchymal stem cell and combination administration groups, and after 30 days, no tumors were observed in 9 mice in the mesenchymal stem cell group, and all 10 mice in the combination administration group showed tumor disappearance (Fig. 16).

[0164] 2) Confirmation of anti-tumor immune memory effect through combination with mesenchymal stem cells (MSCs)

[0165] Based on the experiment in Fig. 16, a re-challenge experiment was conducted to confirm the anti-tumor immune memory effect through combination with mesenchymal stem cells.

[0166] The control group was euthanized in accordance with the Animal Ethics Act, and a re-experiment was conducted with a total of 29 animals, including 9 animals from the mesenchymal stem cell group, 10 animals from the combined administration group, and 10 animals from a new control group. After a 15-day rest period, the mesenchymal stem cell group and the combined administration group were injected with 1 x 10 MC-38, a mouse colon cancer cell line. 5 The control group (10 mice), mesenchymal stem cell group (9 mice), and combination therapy group (10 mice) were re-vaccinated.

[0167] After administering tumor cells, tumor size was measured. The tumor volume of the control group grew the largest, while the mesenchymal stem cell group showed a tendency to slightly decrease. In the combination treatment group, tumors grew in four mice, but the size was not large, and in six mice, tumor growth was not observed at all from the first tumor measurement date to the end date. Significance was confirmed in the mesenchymal stem cell group and the combination treatment group (Fig. 17).

[0168] After tumor measurement, the mice were necropsied. The spleens were removed to examine the immune-related factor white pulp in the spleen. After removal, the spleens were fixed in 10% formalin and paraffin blocks were prepared. Slides were prepared using a microtome, and the prepared slides were stained with H&E. When comparing the spleens between each group, white pulp was found to be significantly increased in the combination treatment group. White pulp is indicated by white letters WP (Fig. 18).

[0169] To confirm the correlation between tumor volume and white pulp through a re-challenge experiment, an immune distribution map was created (Fig. 19). Immunized individuals, indicated by red circles, were tumor-free and exhibited a distribution with increased white pulp. Furthermore, as tumor size increased, white pulp decreased.

[0170] Confirmation of antitumor activity through combined administration with peptide vaccine

[0171] To explore the pharmacological effects of Meti-101, xenograft models were prepared using TC-1-Luc, a mouse-derived lung cancer cell line, divided into four groups: control group (10 mice), Meti-101 (10 mice), peptide vaccine (10 mice), and combined administration of peptide vaccine and Meti-101 (10 mice). 1x10 of the TC-1-Luc cell line was implanted into the flank of the mouse. 5 was administered subcutaneously, and the tumor size was 150 mm after tumor cell administration. 3 From the first day until the end of the experiment, tumor occurrence was confirmed (palpated) twice a week and the long and short axis sizes of the tumors were measured using an electric caliper.

[0172] Tumor size (mm) 3 ) = (long axis) x (short axis 2 ) / 2

[0173] Meti-101 was administered subcutaneously at a dose of 20 mg / kg twice daily for two weeks, and the peptide vaccine was administered intramuscularly at six-day intervals. Seven days after administration, a difference in tumor size was observed between the peptide vaccine and co-administration group compared to the control group, and from day 12, a difference in tumor size between the control group and Meti-101 was observed (56%). From day 15, a significant reduction in tumor size was observed in the peptide vaccine and co-administration group (61%) (Fig. 20).

[0174] Confirmation of antitumor activity through combined administration of IL-7 and Meti-101

[0175] To explore the pharmacological effects of Meti-101, xenograft models were prepared using MC-38, a mouse-derived colon cancer cell line, divided into four groups: control (10 mice), Meti-101 (10 mice), IL-7 (10 mice), and co-administration of IL-7 and Meti-101 (10 mice). 1x10 MC-38 cell line was injected into the flank of the mouse. 5 was administered subcutaneously, and from 7 days after tumor cell administration until the end of the experiment, tumor occurrence was confirmed (palpated) twice a week and the long and short axis sizes of the tumors were measured using an electric caliper.

[0176] Tumor size (mm) 3 ) = (long axis) x (short axis 2 ) / 2

[0177] Meti-101 was administered subcutaneously at a dose of 20 mg / kg twice daily for two weeks, and IL-7 was administered intramuscularly once 7 days after tumor cell administration. From 7 days after administration, the difference in tumor size between the IL-7 and Meti-101 groups increased, and from 10 days onward, the tumor size increased in the control group, IL-7, and Meti-101 groups, but the control group mostly had a tumor size of 500 to 1000 mm. 3Tumors grew to 500–1000 mm in IL-7 3 As the tumors grew, we were able to confirm that the number of individuals decreased significantly. Metit-101 also increased as in the two groups above. In the combination treatment group, the tumor size was confirmed to be significantly reduced compared to the three groups. At the end of the experiment, the tumor size in the control group was 500 to 2000 mm. 3 It was evenly distributed up to 300~2000mm in the IL-7 group. 3 It was confirmed that the distribution was evenly distributed up to 500 ~ 1500mm in the Meti-101 group. 3 It was distributed in 1500mm 3 No abnormal tumors were observed. In the combination therapy group, the tumors were 300 to 1000 mm 3 It was found that the tumor size was significantly reduced while being evenly distributed (Fig. 21)

[0178] Example 5: Apoptosis and necrosis caused by calcium lactate

[0179] HCT116 colon cancer cells were cultured in RPMI1640 medium containing 10% FBS and 1% penicillin / streptomycin, serum-free RPMI1640 medium without FBS, and serum-free RPMI1640 medium treated with 2.5 mM calcium lactate for 2 hours at 37°C under 5% CO2 and 1% O2 conditions. After completion of culture, cell images were obtained using an optical microscope.

[0180] Figures 22 to 24 are photographs of colon cancer cells cultured in a medium containing 10% FBS (Figure 22), colon cancer cells cultured in a serum-free medium (Figure 23), and colon cancer cells cultured in a serum-free medium treated with 2.5 mM calcium lactate (Figure 24). It was confirmed that the presence or absence of serum made no difference in 2-hour culture under low-oxygen conditions. It was found that colon cancer cells cultured in a serum-free medium containing 2.5 mM calcium lactate underwent apoptosis necrosis.

[0181] Example 6: Apoptosis and necrosis caused by calcium lactate according to composition

[0182] HCT-116 colon cancer cell lines were cultured in serum-free RPMI1640 medium and serum-free RPMI1640 medium treated with 2.5 mM calcium lactate at 37℃, 5% CO2, 1% O2, and 37℃, 5% CO2 for 2 hours. After culture, colon cancer cells were photographed with an optical microscope to identify them. To confirm that apoptosis had occurred in serum-free RPMI1640 medium treated with 2.5 mM calcium lactate, the medium was removed, washed once with saline, treated with 1 ml of trypsin-EDTA, and cultured for 1 minute to detach the colon cancer cells. The colon cancer cells were collected with 1 ml of saline and transferred to an Enpendorf tube. Clumped colon cancer cells were dissolved, and 10 μl of the cell suspension was mixed with 10 ml of trypan blue for staining. 10 ml of dyed colon cancer cell suspension was placed on a hemocytometer and the number of viable cells was measured.

[0183] When the experiment was conducted under the above conditions, colon cancer cells in serum-free medium containing 2.5 mM calcium lactate underwent apoptosis regardless of the general culture conditions (Fig. 25, upper right) and hypoxic conditions (Fig. 25, lower right). Colon cancer cells cultured in serum-free medium without 2.5 mM calcium lactate survived both the general culture conditions (Fig. 25, upper left) and hypoxic conditions (Fig. 25, lower left). When the survival of colon cancer cells treated with 2.5 mM calcium lactate was measured using trypan blue staining compared to the control group, it was found that more than 99% of colon cancer cells were dead (Fig. 26).

[0184] The above results confirmed that treatment with 2.5 mM calcium lactate in serum-free medium could induce apoptosis in almost all colon cancer cells, regardless of atmospheric conditions.

[0185] Example 7: Apoptosis and necrosis phenomenon according to calcium lactate and representative cancer cell culture media

[0186] HCT-116 colon cancer cells were cultured in three media commonly used for cancer cell culture (DMEM, IMEM, and RPMI1640) in the absence of serum and supplemented with 2.5 mM calcium lactate. The cells were cultured for 2 hours at 37°C in an atmosphere of 5% CO2 and 1% O2, and images were taken using an optical microscope to observe apoptosis and necrosis. To quantify colon cancer cell death, the medium was removed, the cells were washed once with saline, and 1 ml of trypsin-EDTA was added. After 1 minute of incubation, the colon cancer cells were detached. The colon cancer cells were collected with 1 ml of saline and transferred to an EP tube. Clumped colon cancer cells were lysed, and 10 μl of the cell suspension was mixed with 10 ml of trypan blue for staining. 10 ml of the stained colon cancer cell suspension was placed in a hemocytometer, and the number of viable cells was counted.

[0187] Figure 27 shows that when the HCT-116 colon cancer cell line was cultured in serum-free DMEM, IMEM, and RPMI1640 media containing 2.5 mM calcium lactate for 2 hours, apoptosis was observed in RPMI1640 media (Figure 27, right). When DMEM and IMEM were treated with 2.5 mM calcium lactate, apoptosis of colon cancer cells did not occur (Figure 27, left, Figure 27, middle).

[0188] In order to compare the degree of apoptosis of colon cancer cells according to three types of media in Fig. 28, the number of live colon cancer cells was measured using a hemocytometer and presented in a graph. The number of live colon cancer cells cultured in serum-free DMEM and IMEM media treated with 2.5 mM calcium lactate was measured to be around 1 million per ml, but the amount of live cells cultured in RPMI1640 media was found to be significantly reduced to around 4,000 per ml. Through the above experiment, it can be confirmed that calcium lactate specifically induces apoptosis of cancer cells in RPMI1640 media.

[0189] Example 8: Immune factor activation in human colon cancer cells by treatment with METI-101 in serum-free RPMI1640 medium.

[0190] Human colon cancer cells, HCT-116, were cultured in serum-free RPMI1640 medium sold by Welgene and treated with METI-101. In experiments with varying time, the concentration of METI-101 was treated at 2.5 mM, and the incubation time was set to 1 hour for experiments with varying concentrations. Proteins secreted into the cell (IFNα, GM-CSF, IL-1β) were analyzed by enzyme-linked immunosorbent assay using cell culture fluid. Intracellular signaling proteins and membrane proteins were analyzed by immunoblotting using total cell protein. Finally, the interferon family, which plays a key role in the immune response, was identified at the molecular biological level using real-time polymerase chain reaction.

[0191] Interferon alpha secreted by cells was secreted about twice as much when exposed to 2.5 mM METI-101 in serum-free medium for 1 hour compared to cells without METI-101. (Fig. 29, first left) IFNAR1, a transmembrane receptor that recognizes interferon, also showed a significant increase in mRNA expression level at 1 hour. (Fig. 31, first left) Although the mRNA expression level of IFNAR2, which forms a heterodimer with IFNAR1, did not increase, the intracellular protein significantly increased at 1 hour. (Fig. 31, second from the left, Fig. 30, first from the left) In addition, it was confirmed that phosphorylation of the STING protein, which promotes interferon and pro-inflammatory cytokines, occurred and changed into an active form, and the protein level of major histocompatibility complex 1 (MHC class 1), an antigen-presenting protein, increased. (Fig. 30, first left, Fig. 30, right)

[0192] Treatment with 2.5 mM METI-101 in serum-free medium resulted in phosphorylation of STING and increased synthesis of interferon, as evidenced by the mRNA synthesis of IFNα and IFNβ. When cultured with METI-101 in serum-free medium for 2 hours, interferon mRNA synthesis increased two-fold (Fig. 31, third from the left, fourth from the left, fifth from the left).

[0193] When METI-101 was administered to human cancer cells in a concentration-dependent manner, the secretion of granulocyte-macrophage colony-stimulating factor (GM-SCF), which functions as a growth factor for leukocytes, and IL-1β, which promotes immunity, began to increase significantly from 2.5 mM METI-101. (Figure 29, second from the left, third from the left)

[0194] Cancer cells treated with METI-101 at 2.5 mM or higher in serum-free medium produce and secrete interferon and pro-inflammatory cytokines through intracellular STING signaling, and activate the immune response by increasing antigen markers and interferon receptors.

[0195] Example 9: Reduction of biomarkers due to tumor-associated antigen presentation and cancer cell death by treatment with METI-101 at various concentrations in serum-free RPMI1640 medium.

[0196] Human colon cancer cells (HCT-116), human pancreatic cancer cells (AsPC-1), and human non-small cell lung cancer cells were cultured in serum-free RPMI1640 medium sold by Welgene and treated with METI-101 at various concentrations. The incubation time was fixed at 1 hour, and enzyme-linked immunosorbent assay was performed on the cell cultures for tumor-associated antigen protein (TSPAN8) and tumor marker (CA9) that are specifically produced by cancer cells for 1 hour.

[0197] TSPAN8, a tumor-associated antigen-presenting protein, increased to a very high level when HCT-116 cells were treated with 2.5 mM METI-101, and although it decreased by about half when METI-101 was treated with 5.0 mM, it still maintained a high level compared to the control group. (Fig. 32, first from the left) Unlike HCT-116, AsPC-1 cells and H1299 cells maintained TSPAN8 expression at a very high level starting from a low concentration of 1.5 mM METI-101. Similar to HCT-116, the secretion of tumor-associated antigen-presenting protein decreased as the concentration increased. (Fig. 32, second and third from the left)

[0198] Cancer cells maintain high or low levels of specific proteins or enzymes depending on their type and characteristics. CA9 enzyme is used as one of the representative tumor markers. High levels of CA9 were expressed in human colon cancer cells, HCT-116, and when treated with METI-101, apoptosis of cancer cells occurred, and CA9 was confirmed to decrease in the cell culture medium. (Figure 33, first left) H1299 cells showed the same pattern as HCT-116, and when treated with METI-101, CA9 secretion rapidly decreased from 1.5 mM METI-101 due to apoptosis. AsPC-1 cells showed a concentration-dependent decrease in CA9. (Figure 33, second and third from the left)

[0199] The above results show that when METI-101 is treated in serum-free medium, tumor cells are killed as shown by CA9 results and simultaneously present the tumor-associated antigen TSPAN8.

[0200] Example 10: Secretion of damage-associated molecular patterns (DAMPs) and immunogenic cell death (ICD) due to treatment with METI-101 at various concentrations in serum-free RPMI1640 medium.

[0201] Human colon cancer cells, HCT-116, were cultured in serum-free RPMI1640 medium sold by Welgene and treated with METI-101 at various concentrations. The culture time was fixed at 1 hour, and apoptosis, classified as immunogenic cell death, indicates damage-associated molecular types. In this experiment, damage-associated molecular types were identified in the cell culture medium. DNA, a nucleic acid-type damage-associated molecular type, was isolated using a kit using silica adsorption, and RNA and dsRNA were isolated using TRI solution. DNA and RNA were quantified using a microspectrophotometer (Nanodrop), and dsRNA was quantified using an enzyme-linked immunosorbent assay.

[0202] Other types of damage-associated molecules were assayed using enzyme-linked immunosorbent assay. When nucleic acids were isolated from cell culture media, DNA and RNA in the culture media increased when METI-101 2.5 mM was treated for 1 hour in serum-free media. (Fig. 34, first and second from the left) When dsRNA was quantified after METI-101 2.5 mM was treated for 1 hour in serum-free media, it was confirmed that a high level of dsRNA was present in the media compared to the control group. (Fig. 34, third from the left) Damage-related molecule types other than nucleic acids were confirmed by enzyme-linked immunosorbent assay, including proteins such as HMGB1, Calreticulin, and HSP90, and a significant increase in Calreticulin and HSP90 in the cell culture media occurred from 1.5 mM. (Fig. 35, second and third from the left) HMGB1 showed a tendency to increase in METI-101 1.5 mM, but no significant difference was observed, and it increased to a high level compared to the control group in METI-101 2.5 mM. (Fig. 35, left) First) Finally, the organic molecule ATP was quantified using colorimetry. A significant difference was observed from the control group starting at a low concentration of 1.5 mM METI-101, and the amount of ATP in the cell culture medium increased in a concentration-dependent manner (fourth from the left, Figure 35).

[0203] Quantification of damage-associated molecules in cell culture media confirmed that METI-101 induces apoptosis in cancer cells. Furthermore, apoptosis releases intracellular substances, releasing specific biomolecules that induce an immune response and contribute to immunogenic cell death. These damage-associated molecules relay information to pattern recognition receptors (PRRs) on immune cells, enhancing overall immunity against cancer cells.

[0204] Example 11: Induction of apoptosis by METI-101 through intratumoral injection in mice xenografted with human colon cancer cells, HCT-116.

[0205] Tumors were formed in nude mice by subcutaneously injecting HCT-116 cells, a human colon cancer cell line. Tumors were prepared by mixing serum-free RPMI 1640 medium and METI-101 at a concentration of 54 mM and immediately injected intratumorally using an insulin syringe. After the animal experiment, tumor tissue was immunohistochemically stained for phosphorylated MLKL, a marker of apoptosis and necrosis (Fig. 36, top).

[0206] Tissues that were not injected with METI-101 do not show phosphorylated MLKL, and cancer cells are located normally. (Figure 36, bottom, first from the left) Around the tissue directly injected with METI-101, apoptotic cells are located, and phosphorylated MLKL is stained intensely. This is the area where the tissue collapses, directly and rapidly reducing the tumor size. (Figure 36, bottom, second from the left) Areas surrounding the directly injected area can also be confirmed to be phosphorylated and stained with MLKL. The surrounding area slowly dies as apoptotic cells, which further enhances the immune response. (Figure 36, bottom, third from the left)

[0207] This animal experiment demonstrates that direct intratumoral injection of METI-101 induces rapid cell death at the injection site and death in surrounding areas, resulting in a reduction in overall tumor size and the effect of immunogenic cell death.

[0208] Example 12: Apoptosis and lymphocyte recruitment of METI-101 through intratumoral injection in mice xenografted with human colon cancer cells, HCT-116.

[0209] In Example 11, the tissue was stained using hematoxylin-eosin, a tissue staining technique. The imaged tissue shows the area directly injected with METI-101, where apoptotic cells are concentrated. As shown in Figure 29, METI-101 treatment increases GM-CSF levels, and lymphocytes are observed surrounding apoptotic cells within the tumor (second from the left in Figure 29, Figure 37).

[0210] Example 13: Induction of apoptosis and necrosis by METI-101 through intratumoral injection in mice transplanted with CT26, a colon cancer cell line, and its combined effect with standard radiotherapy

[0211] Based on the previous example, an experiment was conducted to determine whether systemic immunity against cancer cells was successfully completed when METI-101 was directly injected to induce apoptosis. CT26 cells, a mouse-derived colon cancer cell line, were injected subcutaneously under the skin of mice to form tumors. The formed tumors were treated with standard radiotherapy and direct administration of METI-101, either individually or simultaneously. Radiotherapy was performed once at a high dose, and METI-101 was directly injected into the tumor four times over two weeks. 1 time

[0212] METI-101 was administered at a concentration of 54 mM in serum-free medium (Fig. 38, top). After undergoing the above experimental procedures, all mice underwent surgery to remove their tumors. After a brief recovery period, all mice received a subcutaneous injection of CT26 cells at the same initial cell count. Tumor formation was monitored for two weeks to confirm the presence or absence of tumors (Fig. 38, bottom).

[0213] Example 14: Induction of apoptosis and necrosis by METI-101 through intratumoral injection in mice transplanted with CT26, a colon cancer cell line, and its combined effect with standard radiotherapy

[0214] As a result of conducting an animal experiment according to the experimental method of Example 13, the control group and the group that received direct intratumoral injection of RPMI1640 showed that cancer cells grew normally and grew to an average of 2 to 2.5 mm. 3 In contrast, the group that received standard radiotherapy showed a significant decrease in the size of cancer cells to an average of 0.56 mm 3 . The group that received direct intratumoral injection of METI-101 54 mM in serum-free medium showed an average tumor size of 0.22 mm 3 . 3 Tumor sizes were smaller than those of standard radiotherapy. The group that received both treatments had an average tumor size of 0.02 mm. 3 You can see that it has been reduced to a smaller level (left photo and graph of the left picture of Fig. 39).

[0215] To confirm apoptosis, a type of immunogenic cell death, tumor tissue was stained for phosphorylated MLKL using immunohistochemistry. No MLKL phosphorylation occurred in tumors treated with standard radiotherapy. MLKL phosphorylation was clearly evident in tumors injected with METI-101. When both treatments were administered together, cancer cells died, forming pores, and MLKL phosphorylation occurred in the remaining cells (right photo of the left image in Figure 39).

[0216] When CT26 cells were re-injected, all mice in the control group and those injected with RPMI1640 medium developed tumors. None of the mice in the group receiving standard radiation therapy or direct intratumoral injection of METI-101 developed tumors (Fig. 39, right graph).

[0217] Both standard radiation therapy and direct intratumoral injection of METI-101 significantly reduced tumor size, and when administered simultaneously, tumors were reduced to the point of complete disappearance. As in the previous examples, METI-101 activates the immune system through apoptosis, shrinks tumors, and prevents recurrence through immune memory.

[0218] Example 15: Apoptosis and necrosis induced by METI-101 in NaH2PO4+ NaHCO3 solution and RPMI1640

[0219] Apoptosis was confirmed in human colon cancer cells, HCT-116, by treating 2.5 mM METI-101 in a solution of NaH2PO4+ NaHCO3 dissolved in distilled water. As a negative control, PBS and PBS with 2.5 mM METI-101 were treated, and as a positive control, RPMI1640 from Welgene was treated with 2.5 mM METI-101. The experimental groups were selected as a solution of NaH2PO4+ NaHCO3 dissolved in distilled water at the same molar concentration as the composition of RPMI1640 and a solution of NaH2PO4+ NaHCO3 dissolved in distilled water adjusted to pH 7.4, and treated with 2.5 mM METI-101. The drug-treated cells were cultured under hypoxic conditions for 2 hours. Turbidity was also measured at a wavelength of 660 nm after treating with 2.5 mM METI-101.

[0220] Compared to before treatment, cancer cells treated with PBS alone were all floating on the bottom, while cancer cells treated with METI-101 2.5 mM in PBS showed a phenomenon of sticking to the bottom due to the matching osmotic pressure. (Figure 40, top) Cancer cells treated with METI-101 2.5 mM in Welgene's RPMI1640 showed apoptosis necrosis in the same way as in the previous example. (Figure 40, bottom left, first) When METI-101 2.5 mM was treated in a solution of NaH2PO4 + NaHCO3 dissolved in distilled water and a solution of NaH2PO4 + NaHCO3 dissolved in distilled water to adjust the pH to 7.4, the same phenomenon as Welgene's RPMI1640 was observed. (Figure 40, bottom left, second and third)

[0221] To confirm whether apoptosis was induced and cell death was confirmed, trypan blue staining was performed to measure the number of living cells. The control group treated with PBS and 2.5 mM METI-101 in PBS showed no significant difference in values, and there was a difference between the positive control group and the experimental group. It was confirmed that apoptosis was induced slightly more when METI-101 2.5 mM was treated with a solution of NaH2PO4 + NaHCO3 dissolved in distilled water than when treated with RPMI1640, and it was found that most cells were killed when the pH was adjusted (Fig. 41, top). Turbidity, one of the characteristics that appeared when METI-101 was treated in RPMI1640, also showed the same level of turbidity in a solution of NaH2PO4 + NaHCO3 dissolved in distilled water (Fig. 41, bottom).

Claims

1. a) Calcium lactate and b) A pharmaceutical composition comprising, as an active ingredient, at least one substance selected from the group consisting of phosphate, stem cells, cytokines, cancer cell lines, antigens derived from the cancer cell lines, polynucleotides encoding the antigens, antigen gene constructs in which the polynucleotides are operably linked to a promoter, and expression vectors comprising the gene constructs.

2. In paragraph 1, the cancer cell line-derived antigen is a tumor specific antigen. antigen (TSA) or tumor associated antigen (TAA), The above cytokine is one or more cytokines selected from the group consisting of IL-2, IL-7, IL-12, IL-15, IL-21 and GM-CSF, A pharmaceutical composition characterized in that the above phosphate is monosodium phosphate.

3. A pharmaceutical composition according to claim 1 or 2, characterized in that the composition further comprises a carbonate.

4. A pharmaceutical composition according to claim 1 or 2, characterized in that in the composition, calcium lactate is 2.5 mM to 54 mM and the phosphate is 5 mM or more. 5.a) Calcium lactate and b) A pharmaceutical composition for treating cancer, comprising as an active ingredient at least one substance selected from the group consisting of phosphate, stem cells, cytokines, cancer cell lines, antigens derived from the cancer cell lines, polynucleotides encoding the antigens, antigen gene constructs in which the polynucleotides are operably linked to a promoter, and expression vectors including the gene constructs.

6. In paragraph 5, the cancer cell line-derived antigen is a tumor specific antigen. antigen (TSA) or tumor associated antigen (TAA), The above cytokine is one or more cytokines selected from the group consisting of IL-2, IL-7, IL-12, IL-15, IL-21 and GM-CSF, A pharmaceutical composition for treating cancer, characterized in that the above phosphate is monosodium phosphate.

7. A pharmaceutical composition for treating cancer, characterized in that the composition further comprises a carbonate according to claim 5 or 6.

8. A pharmaceutical composition for treating cancer, characterized in that in the composition of claim 5 or 6, calcium lactate is 2.5 mM to 54 mM and the phosphate is 5 mM or more.

9. A pharmaceutical composition for treating cancer, characterized in that in paragraph 5, the cancer is selected from the group consisting of colon cancer, lung cancer, stomach cancer, glioma, liver cancer, melanoma, kidney cancer, urothelial cancer, head and neck cancer, Merkel cell carcinoma, prostate cancer, blood cancer, breast cancer, colon cancer, rectal cancer, pancreatic cancer, brain cancer, ovarian cancer, bladder cancer, bronchial cancer, skin cancer, cervical cancer, endometrial cancer, esophageal cancer, thyroid cancer, bone cancer, and combinations thereof. 10.a) Calcium lactate and b) A cancer vaccine composition comprising, as an active ingredient, at least one substance selected from the group consisting of phosphate, stem cells, cytokines, cancer cell lines, antigens derived from the cancer cell lines, polynucleotides encoding the antigens, antigen gene constructs in which the polynucleotides are operably linked to a promoter, and expression vectors including the gene constructs.

11. In the 10th paragraph, the cancer cell line-derived antigen is a tumor specific antigen. antigen (TSA) or tumor associated antigen (TAA), The above cytokine is one or more cytokines selected from the group consisting of IL-2, IL-7, IL-12, IL-15, IL-21 and GM-CSF, A cancer vaccine composition characterized in that the above phosphate is monosodium phosphate.

12. A cancer vaccine composition according to claim 10 or 11, characterized in that the composition further comprises a carbonate.

13. A cancer vaccine composition according to claim 10 or 11, characterized in that in the composition, calcium lactate is 2.5 mM to 54 mM and the phosphate is 5 mM or more.

14. A cancer vaccine composition according to claim 10 or 11, characterized in that the composition is administered intratumoral.

15. A cancer vaccine composition according to claim 10, characterized in that the cancer is selected from the group consisting of colon cancer, lung cancer, stomach cancer, glioma, liver cancer, melanoma, kidney cancer, urothelial cancer, head and neck cancer, Merkel cell carcinoma, prostate cancer, blood cancer, breast cancer, colon cancer, rectal cancer, pancreatic cancer, brain cancer, ovarian cancer, bladder cancer, bronchial cancer, skin cancer, cervical cancer, endometrial cancer, esophageal cancer, thyroid cancer, bone cancer, and combinations thereof. 16.a) Calcium lactate and b) A method for treating or preventing cancer, comprising administering to a subject having a cancer disease a composition comprising, as an active ingredient, at least one substance selected from the group consisting of phosphate, stem cells, cytokines, cancer cell lines, antigens derived from the cancer cell lines, polynucleotides encoding the antigens, antigen gene constructs in which the polynucleotides are operably linked to a promoter, and expression vectors comprising the gene constructs.

17. In paragraph 16, the cancer cell line-derived antigen is a tumor specific antigen. antigen (TSA) or tumor associated antigen (TAA), The above cytokine is one or more cytokines selected from the group consisting of IL-2, IL-7, IL-12, IL-15, IL-21 and GM-CSF, A method for treating or preventing cancer, characterized in that the above phosphate is monosodium phosphate.

18. A method for treating or preventing cancer, characterized in that the composition further comprises a carbonate according to claim 16 or 17.

19. A method for treating or preventing cancer, characterized in that in the composition, calcium lactate is 2.5 mM to 54 mM and the phosphate is 5 mM or more, according to claim 16 or 17.

20. A method for treating or preventing cancer according to claim 16 or 17, characterized in that the composition is administered intratumoral.

21. A method for treating or preventing cancer, characterized in that the cancer in claim 16 is selected from the group consisting of colon cancer, lung cancer, stomach cancer, glioma, liver cancer, melanoma, kidney cancer, urothelial cancer, head and neck cancer, Merkel cell carcinoma, prostate cancer, blood cancer, breast cancer, colon cancer, rectal cancer, pancreatic cancer, brain cancer, ovarian cancer, bladder cancer, bronchial cancer, skin cancer, cervical cancer, endometrial cancer, esophageal cancer, thyroid cancer, bone cancer, and combinations thereof.

Citation Information

Patent Citations

  • Pharmaceutical composition for treating cancer comprising lactate metallic salts

    KR1020160128284A

  • Combination therapy of tetracyclic quinolone analogs for treating cancer

    KR1020180113976A

  • Method for manufacturing shadow mask using electroforming plating and slimming

    KR1020240112672A

  • Lyophilization of nucleic acids in lactate-containing solutions

    WO2011069587A1

  • Method for performing non-thermal ablation of a target tissue

    WO2021181230A1